CARLOS AVILA: Open Payments
NPI 1740921030 · ODESSA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$511 in 14 payments from 10 companies in 2025. Trend: 2023 $332 · 2024 $574 · 2025 $511
Food & beverage: $511
| Company | Payments | Amount |
|---|---|---|
| SCPHARMACEUTICALS INC. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $121 |
| Novo Nordisk Inc | 4 | $83 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Boston Scientific Corporation | 1 | $24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
Products named: FUROSCIX, VOQUEZNA, Ozempic, Kerendia, AUSTEDO XR, MOUNJARO, Rybelsus, CAPLYTA.
Industry payments across TX — which companies pay providers there.
